Status:
UNKNOWN
Long-term Observational Study to Evalution the Safety and Efficacy of FURESTEM-AD Inj.
Lead Sponsor:
Kang Stem Biotech Co., Ltd.
Conditions:
Atopic Dermatitis
Eligibility:
All Genders
19-70 years
Brief Summary
Observational Study to Assess the Safety and Efficacy of FURESTEM-AD lnj. In moderate to Atopic Dermatitis
Detailed Description
This is a observational study, single center, open label, study of safety and Efficacy of FURESTEM-AD Inj. in subjects with moderate to severe Atopic Dermatitis.
Eligibility Criteria
Inclusion
- Subjects participating in this observational study originally participated in study FURESTEM-RA Inj.\[NCT02221258\]
- Subject who understands and voluntarily sign an informed consent form
Exclusion
- In case follow-up is not possible from end of clinical trial Phase 1/2a to end of this study period
Key Trial Info
Start Date :
July 1 2016
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 31 2018
Estimated Enrollment :
14 Patients enrolled
Trial Details
Trial ID
NCT03458624
Start Date
July 1 2016
End Date
December 31 2018
Last Update
March 8 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Seoul ST. Mary's Hospital
Seoul, South Korea